Digest Network Come funziona
Network
/
Società
Qu
Non verificato

QurAlis Corporation

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaSaluteScienza

9 comunicati stampa

Guarda tutti i comunicati
29/12/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
18/12/2025
Eventi
Web e Social Network
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
QurAlis Invited to Present at 44th Annual J.P. Morgan Healthcare Conference
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
02/12/2025
Biotecnologia
Farmaceutica
Salute
QurAlis to Present Data From its Phase 1 Clinical Trial of QRL-101, a Potential Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener, at American Epilepsy Society 2025 Annual Meeting
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
20/11/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Web e Social Network
Fiere
Eventi
QurAlis to Participate in Piper Sandler 37th Annual Healthcare Conference
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
10/11/2025
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Eventi
Fiere
QurAlis to Participate in Upcoming Investor Conferences in November
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
20/08/2025
Biotecnologia
Farmaceutica
Salute
Eventi
QurAlis to Participate in Upcoming Investor Conferences in September
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
18/06/2025
Salute
Mercato Immobiliare
Tecnologia delle costruzioni
Scienza
Farmaceutica
Biotecnologia
QurAlis Announces New Global Headquarters
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0
15/05/2025
Mercato del lavoro
Industria
Scienza
Biotecnologia
Salute
Università
Farmaceutica
Scuola/Istruzione
QurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy
Fonte
QurAlis Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0